Active immunotherapy of cancer has yet to yield effective therapies in the clinic. To evaluate the translatability of DNA-based vaccines we analyzed the profile of T-cell immunity by plasmid vaccination in a murine model, using transcriptome microarray analysis and flow cytometry. DNA vaccination resulted in specific T cells expressing low levels of co-inhibitory molecules (most notably PD-1), strikingly different from the expression profile elicited by peptide immunization. In addition, the T-cell response primed through this dual-antigen-expressing plasmid (MART-1/Melan-A and tyrosinase) translated into a substantial proliferation capacity and functional conversion to antitumor effector cells after tyrosinase and MART-1/Melan-A peptide analog boost. Furthermore, peptide boost rescued the immune response against the subdominant tyrosinase epitope. This immunization approach could be adapted to elicit potent immunity against multiple tumor antigens, resulting in a broader immune response that was more effective in targeting human tumor cells. Finally, this study sheds light on a novel mechanism of immune homeostasis through synchronous regulation of co-inhibitory molecules on T cells, highly relevant to heterologous prime boost approaches involving DNA vaccines as priming agents.
Introduction
Despite promising advances in the field of targeted therapies, malignant melanoma and other solid tumors remain an outstanding unmet medical need, particularly in the unresectable metastatic disease stage, but also in earlier stages such as post-resection with minimal residual disease and high risk of relapse. 1 There is an acute need for therapies that are effective, avoid development of drug resistance, afford durable responses with minimal safety liabilities and potentially complement emerging small-molecule therapies. 2 Nearly two decades since the first 'tumor associated antigens' (TAA) were cloned and sequenced, 3, 4 the design of effective active immunotherapies ('cancer vaccines') remains an important objective. MART-1 (melanoma antigen recognized by T-cells-1)/Melan-A and tyrosinase are tissue-specific antigens with function in supporting melanin synthesis 5, 6 and are highly expressed in malignant melanoma as well as normal melanocytes. Both antigens are highly characterized from an immunological standpoint and encompass major histocompatibility complex (MHC) class-I (A*0201)-restricted epitopes. 7, 8 In several recent clinical studies there have been encouraging reports of success after adoptive T-cell therapy with MART-1/ Melan-A-specific T cells that resulted in objective tumor responses of varying durability, supporting the applicability of this antigen to cancer immunotherapy. 9, 10 Nevertheless, attempts to effectively immunize and elicit objective clinical responses against these two antigens using 'vaccines' have successfully shown immunity but not yet yielded strong evidence of clinical benefit. 11, 12 Similarly, cancer-testes antigens NY-ESO-1 and SSX2 are promising targets for active immunotherapy of cancer, with expression in melanoma and diverse carcinoma as well as other solid tumors. [13] [14] [15] Altogether, numerous clinical studies performed during the last decade showed that almost invariably 'cancer vaccines' yielded a modest clinical response rate (as measured by rigorous RECIST criteria) of no more than 5-10%. 16 Strikingly, though, most responses were quite durable 16 and in line with observations from studies using non-specific immune modulators such as recombinant interleukin-2 17 and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibodies. 18, 19 Previously, in an attempt to improve on the in vivo generation and amplification of TAA-specific T cells, we clinically evaluated the intra-lymph node administration of two individual plasmids encompassing either MART-1/Melan-A or tyrosinase antigen fragments in stage-III and IV melanoma patients with measurable disease. [20] [21] [22] Nevertheless, despite an apparent correlation between immunity and clinical outcome (as measured by time to progression), 20 there were no objective clinical responses (defined by RECIST criteria) in any of these phase-I trials. Evidence from preclinical 23 and clinical studies, especially those involving adoptive T-cell therapy, 9, 10 suggested that a robust, continuous presence of TAAspecific T cells with minimal interference by immune inhibitory mechanisms was a prerequisite for an objective tumor response. In addition, it has been suggested that the effector profile and other less well-understood properties of discrete TAA-specific T-cell subpopulations may also have an important role in tumor regression. 24 Thus, in light of our data and additional information generated independently, 25, 26 we re-evaluated the strengths and limitations of plasmid-based immunization as an option for active immunotherapy in cancer. More specifically, we sought to integrate the concept of immunization by direct intra-lymph node administration with a plasmid prime/peptide boost approach in an attempt to synergize key features of these two immunizing vectors: (i) plasmid priming for induction of a highquality immune response and (ii) peptide boosting for amplification and functional conversion of the immune response. 27 Here, a systematic evaluation of the immune response to plasmids and peptides by gene expression analysis showed a novel mechanism of immune homeostasis through the concerted regulation of co-inhibitory molecules, thus providing a scientific rationale for heterologous prime-boost immunotherapies using DNA as the priming agent.
Materials and methods

Plasmid and peptides for immunization
The pMEL-TYR plasmid (Figure 1a) contains cDNA encoding the epitopes tyrosinase 369-377 (YMDGTMSQV) and MART-1/Melan-A 26-35 A27L (ELAGIGILTV) analog, as well as other fragments from these two antigens. The plasmid was originally referred to as pSEM and described previously. 20 The pNYE-SSX plasmid ( Figure 1a ) contains cDNA encoding multiple copies of NY-ESO-1 157-165 (SLLMWITQV) and SSX2 (KASEKIFYV) epitopes along with other antigen fragments from NY-ESO-1. The peptides used in this study were E-MEL (MART-1/ Melan-A 26-35 A27Nva, ENvaAGIGILTV); 28 E-TYR (tyrosinase 369-377 V377Nva, YMDGTMSQNva); E-NYE (NY-ESO-1 157-165 L158Nva C165V, SNvaLM-WITQV) and E-SSX (SSX2 41-49 A42 V, KVSEKIFYV) (Figure 1b) , designed to bind with higher affinity or more stably to MHC class-I, as compared with the native epitopes (Supplementary Table 1 ). For immunization, the plasmids were formulated at 1.0 or 2.0 mg/ml in 0.25 mM EDTA and 0.5% EtOH, pH 7.6 and lyophilized peptides were reconstituted in water at a concentration of 0.5 mg/ml (E-NYE) or 1.0 mg/ml (E-MEL, E-TYR and E-SSX).
Mouse strains and cell lines
Pathogen-free 8-to 10-week-old female HLA-A2.1 transgenic HHD-1 mice 29 were housed at MannKind Corporation according to IACUC guidelines. All animal studies were reviewed and approved by an IACUC institutional review committee. Chromium-51 ( 51 Cr) release assays were performed with HLA-A2.1 þ human melanoma cells 624.38 and HLA-A2.1 neg 624.28 control cells, and in vivo tumor challenge studies were conducted with NY-ESO-1-transfected 624.38 (624.38-NY) and 624.28 cells (624.28-NY), which express all target antigens MART-1/Melan-A, tyrosinase, SSX2 and NY-ESO-1. These cell lines were cultured in RPMI supplemented with 10% fetal bovine serum, 0.1 mM non-essential amino acids and 0.3 mg/ml L-glutamine (Gibco, Burlington, Ontario, Canada).
Intra-lymphatic immunization HHD-1 mice were injected bilaterally in the inguinal lymph nodes on days 1, 4, 15, 18, 29 and 32 as described previously. 27 Bivalent immunization was achieved by immunizing mice with 25 ml (or 25 mg) of pMEL-TYR (1.0 mg/ml) in both right and left inguinal lymph nodes on days 1, 4, 15 and 18 followed by 25 ml (or 25 mg) injections of E-TYR (1.0 mg/ml) in the right lymph node and 25 ml (or 25 mg) E-MEL (1.0 mg/ml) in the left lymph node on days 29 and 32 as illustrated in Figure 3a .
Tetravalent immunization was achieved as described in Table 2 . In brief, female HHD-1 mice were immunized with a mixture of 100 mg/day pMEL-TYR (2.0 mg/ml) and pNYE-SSX (2.0 mg/ml) plasmids by direct injection into the bilateral inguinal lymph nodes (25 ml or 50 mg per inguinal lymph node). The plasmid-only mice (Group-1) received plasmid injections on days 1, 4, 15, 18, 28, 32, 49 and 53, whereas the plasmid-prime and peptide-boosted mice (Groups 2 and 3) received plasmid injections on days 1, 4, 15 and 18, respectively. Prime-boost animals were then boosted in the right lymph node with 25 ml (or 25 mg) E-TYR (1.0 mg/ml) and in the left lymph node with 25 ml (or 25 mg) E-SSX (1.0 mg/ml) peptides on days 28, 32, 49 and 53 (Group-2), or were boosted in the right lymph node with E-TYR and in the left lymph node with E-SSX peptides on days 28 and 32 followed by injection in the right lymph node with 25 ml (or 12.5 mg) E-NYE (0.5 mg/ml) and in the left lymph node with 25 ml (or 25 mg) E-MEL (1.0 mg/ml) peptides on days 49 and 53 (Group-3).
Tetramer analysis of T-cell immunological response
The specific T-cell response in immunized animals was quantified 7 days after the plasmid immunizations and 7 days after the peptide boost by co-staining mononuclear cells isolated from peripheral blood after density centrifugation (Lymphocyte Mammal; Cedarlane Labs, Burlington, Ontario, Canada) with HLA-A*0201 MART-1/Melan-A (ELAGIGILTV)-PE MHC tetramer (T02001; Beckman Coulter, Brea, CA), HLA-A*0201 tyrosinase (YMDGTMSQV)-APC MHC tetramer (T02001; Beckman Coulter), rat anti-mouse CD8a (Ly-2)-PerCP monoclonal antibody (BD Biosciences, San Jose, CA) and rat anti-mouse CD62L-FITC monoclonal antibody (BD Biosciences) for 1 h at room temperature. To measure tetravalent immune responses in individual mice, peripheral blood mononuclear cell (PBMC) isolated from blood was divided into a second sample and co-stained with HLA-A*0201 NY-ESO-1 (SLLMWITQV)-PE MHC tetramer (Beckman Coulter) and HLA-A*0201 SSX2 (KASEKIFYV)-APC MHC tetramer (Beckman Coulter), rat anti-mouse CD8a (Ly-2)-PerCP monoclonal antibody and rat anti-mouse CD62L-FITC monoclonal antibody for 1 h at room temperature. For programmed death-1 (PD-1) expression studies, PBMCs from immunized animals were co-stained with MART-1/Melan tetramer (Beckman Coulter), PerCPconjugated rat anti-mouse CD8a (Ly-2) and PE-conjugated PD-1 antibody (Pharmingen, San Diego, CA). Data were collected using a FACS Calibur flow cytometer (BD Biosciences) and analyzed using the CellQuest software. A 100-ng weight of total RNA from the sorted T-cell populations was used to make the cRNA probe for the microarray. The pooled RNA samples from each T-cell population were split into two and used to run technical replicates of the GeneChips. RNA and cRNA quality was determined by Nanodrop spectrophotometry and GCOS, respectively, and images were converted into numerical values using the Affymetrix MAS 5 software by Asuragen (Austin, TX). The gene expression analysis was performed by using a one-way analysis of variance with a P-value of o0.01, comparing expression in the median value of duplicate pMEL-TYR plasmid or E-MEL peptide arrays compared with that of naı¨ve control arrays. The pairing option used was as follows: all conditions against naı¨ve control with a twofold increase or decrease in mRNA expression set as the cut-off value for a significant difference in mRNA expression levels. Expression pattern clusters were defined using the hierarchical clustering function in GeneSpring v10 (Agilent Technologies, Santa Clara, CA) by using the average signal from the two replicate arrays and normalizing for expression across all arrays.
ELISPOT assay
For interferon-g (IFN-g) (U-Cytech, Utrecht, The Netherlands) enzyme-linked immunosorbent spot (ELISPOT) analysis, splenocytes were isolated 10 days after the peptide boost and mononuclear cells, after density centrifugation (Lympholyte Mammal; Cedarlane Labs), were resuspended in HL-1 serum-free medium (77201; Cambrex Corporation, East Rutherford, NJ) and stimulated with 10 mg/ml of MART-1/Melan-A native peptide (EAAGIGILTV) and tyrosinase 369-377 native peptide (YMDGTMSQV) in 96-well filter membrane plates (Multi-screen IP membrane 96-well plate; Millipore, Billerica, MA). To measure tetravalent ELISPOT responses in individual mice, PBMC isolated from spleen was divided into two additional 96-well plates and stimulated with 10 mg/ml of NY-ESO-1 (SLLMWITQV) and SSX2 (KASEKIFYV) native peptides. The plates were incubated at 37 1C and 5% CO 2 for 48 h before development. The anti-IFN-g antibodies and assay development reagents were used according to the manufacturer's instructions.
In vivo analysis of T-cell response by CFSE cytotoxicity Evaluation of cytotoxic immunity in vivo was performed by carboxyfluorescein succinimidyl ester (CFSE, Molecular Probes, Eugene, OR) assay. Specific targets were prepared from splenocytes (Figures 5a and b) isolated from syngeneic mice by density centrifugation (described above) and resuspended in HL-1 serum-free medium at a concentration of 10 7 cells/ml. Different aliquots of target cells were pulsed with 10 mg/ml tyrosinase 1-9 (MLLAVLYCL) as a peptide control, 10 mg/ml MART-1/Melan-A 26-35 A27L (ELAGI-GILTV) peptide and 10 mg/ml tyrosinase 369-377 (YMDGTMSQV) for 1 h at 37 1C and 5% CO 2 . Peptide-pulsed cells were washed and resuspended in phosphate-buffered saline and then labeled separately with 0.3 mM CFSE (low) , 1.5 mM CFSE (med) and 6 mM CFSE (high) , respectively, for 15 min at room temperature according to the manufacturer's instructions (Figures 5a  and b) . Immunized or naı¨ve control HHD-1 mice were intravenously injected in the tail vein with 10 7 cells made up of an equal ratio of CFSE (low) , CFSE (med) and CFSE (high) labeled target cell populations. At 18 h, mononuclear cells from spleen were isolated by density centrifugation (described above) and the frequency of CFSE-positive cells was analyzed by flow cytometry, by gating on the lymphocyte population and enumerating the percentage of CFSE-positive cells in the FL-1 fluorescent channel. A decrease in the percentage of CFSE (high) (tyrosinase 369-377) or CFSE (med) (MART-1/ Melan-A 26-35) target cells relative to CFSE (low) tyrosinase 1-9 labeled peptide control cells indicated specific lysis in vivo. The formula used to calculate the % specific lysis is as follows:
In another series of experiments (Table 3) , specific targets were prepared by incubating 624.38-NY HLA-A2 þ human tumor cells with 2.5 mM CFSE (high) and control targets were generated by labeling 624.28-NY HLA-A2 neg cells with 0.25 mM CFSE (low) . Immunized HHD-1 mice were intravenously injected with 10 7 cells made up of an equal ratio of CFSE (high) target cells and CFSE (low) control cells, and un-immunized HHD-1 mice were injected to served as naı¨ve controls. At 18 h, mononuclear cells from lungs were isolated and CFSE-positive cells were analyzed by fluorescence-activated cell sorting (FACS) as described above. In this experimental model, evaluation of in vivo target cell clearance over a short interval of time of less than 24 h is absolutely crucial to preclude the confounding, delayed effect of the innate immunity vis-a-vis human tumor cells (data not shown).
51
Cr release assays For ex vivo 51 Cr release assay, B-cell blasts were differentiated from naı¨ve HHD-1 spleen cell cultures in the presence of 25 mg/ml lipopolysaccharide and 10 mg/ml dextran sulfate for 72 h and used as antigen-presenting cells (APC). Splenocytes isolated from five immunized HHD-1 mice were pooled and stimulated with both murine interleukin-2 (10 U/ml) and irradiated (30 Cr-labeled 624.38 and 624.28 cells in U-bottom 96-well plates at effector to target (E:T) ratios of 10, 30 and 100 to 1. After 4-h incubation, the supernatants were harvested and released 51 Cr was determined using a gamma counter. Spontaneous release was determined by incubating the target cells with medium and maximum release was induced by incubating the target cells with 2% sodium dodecyl sulfate. Specific lysis was measured as follows:
% specific release ¼ ½ðexperimental release À spontaneous releaseÞ =ðmaximum release À spontaneous releaseÞÂ100%:
Statistical analysis
Statistical analysis between selected groups was performed using a two-tailed Student's t-test assuming equal variances. Differences were considered statistically significant for Po0.05.
Results
Comparative analysis of immune response elicited by plasmid and peptide in mouse To investigate the molecular pathways that are modulated in CD8
þ T cells after vaccination with a DNA molecule or with peptides, we compared the gene expression profiles of CD8 þ T cells from naı¨ve control mice to that of CD8 þ T cells from either pMEL-TYR plasmid or E-MEL (MART-1/Melan-A) peptide-vaccinated mice. Splenocytes from vaccinated mice were pooled and sequentially purified using magnetic, followed by electronic cell sorting yielding a purity of B98% CD8 þ /MART-1/Melan-A tetramer þ cells (Supplementary Figure 1A) . This data was compared to a population of CD8 þ T cells (B98%) purified using a similar protocol from naı¨ve control mice. To investigate the global gene expression profiles, RNAs from the pooled populations of CD8 þ / MART-1/Melan-A tetramer þ cells were hybridized to Affymetrix mouse 430A 2.0 GeneChips with 45 000 probesets encompassing the mouse transcriptome. The mRNA expression profiles from the pMEL-TYR plasmid and E-MEL peptide CD8
þ /Melan-A-specific T-cell pools were compared to the expression profile of CD8 þ T cells from naı¨ve control mice. A box and whiskers plot (Supplementary Figure 1B) shows the expression and reproducibility of chips across the individual GeneChips. The RNA from CD8 þ /Melan-A-specific T cells from E-MEL-peptide vaccinated mice showed a larger percentage of dysregulated genes compared with CD8 þ /Melan-A-specific T cells from pMEL-TYR plasmid-vaccinated mice (Supplementary Figure 1B) . Gene expression was normalized and used in a hierarchical clustering analysis, encompassing genes that showed a 42-fold change in expression compared with the naı¨ve control CD8 þ T cells (Figure 2a and Supplementary Table 2 ). This resulted in a subset of approximately 1400 probesets (corresponding to 807 unique genes with annotations) that were used in the hierarchical clustering analysis shown in Figure 2a .
The clustering analysis showed a number of uniquely upregulated genes (n ¼ 65) (as described in the NCBI Entrez Gene database) in the CD8 þ /Melan-A-specific T cells from pMEL-TYR plasmid-versus E-MEL peptide-immunized mice (Supplementary Table 2) . Similarly, we observed uniquely downregulated genes (n ¼ 131). The patterns also showed genes that are concordantly dysregulated in both treatment populations compared with the naı¨ve control, identifying genes downregulated (n ¼ 176) or upregulated (n ¼ 436) in CD8 þ /Melan-A-specific T cells from the pMEL-TYR plasmid and E-MEL peptide treatment groups (Figure 2a  and Supplementary Table 2 ). Supplementary Table 2 contains a list of the top 50 genes dysregulated in CD8
þ / Melan-A-specific T cells isolated from pMEL-TYR plasmid or E-MEL peptide-immunized mice relative to CD8
þ T cells isolated from naı¨ve control mice. We observed a number of dysregulated co-inhibitory receptor genes in the CD8 þ /Melan-A-specific T cells from pMEL-TYR plasmid or E-MEL peptide-treated animals as compared with CD8 þ T cells from naı¨ve control animals and focused on these regulatory genes as they may be relevant to the differences seen in immune responses afforded by plasmid and peptide vaccination (Figure 2b) .
A notable phenotypic characteristic of pMEL-TYR plasmid-induced specific CD8 þ T cells is the coordinately lower expression of mRNA for cell-surface inhibitory receptors. We have focused on PD-1 and CTLA-4, which are known to regulate CD8 þ T-cell exhaustion and/or tolerance to self tissues. The level of mRNA for PD-1 (Pdcd1) was found to be two-fold higher in pMEL-TYR plasmid-induced, CD8
þ /Melan-A-specific T cells, but in contrast, was eight-fold higher in E-MEL peptideinduced, CD8
þ /Melan-A-specific T cells, when compared with that in CD8 þ T cells from naı¨ve controls (Figure 2b) . Similarly, CTLA-4 (Ctla4) mRNA levels were five-fold higher in E-MEL peptide-induced, CD8
þ / Melan-A-specific T cells as compared with that in CD8 þ T cells from naı¨ve controls, and downregulated approximately two-fold in pMEL-TYR plasmid-induced, CD8
þ / Melan-A-specific T cells (Figure 2b) . A similar trend was seen for PTGER2 and LAG3 (molecules with inhibitory function), with mRNA levels lower in pMEL-TYR plasmid-induced, CD8
þ /Melan-A-specific T cells compared with that in E-MEL peptide-induced, CD8
þ / Melan-A-specific T cells (Figure 2b) . Furthermore, the differential expression profile of PD-1 on MART-1/ Melan-A antigen-specific CD8 þ T cells elicited by plasmid or peptide immunization was confirmed by flow cytometry and showed a significantly higher surface expression and frequency of PD-1 on peptide-induced T cells as compared with plasmid-immunized mice (Table 1) . These data, in addition to results showing the expression of CD62L (L-selectin), indicating the central memory phenotype of pMEL-TYR plasmid-induced CD8 þ T cells, may help explain the high proliferative potential of these cells, which undergo a dramatic expansion upon heterologous boosting with peptide, and is in stark contrast with the limited effect of peptide boost in mice primed with peptide. 27 Optimization of a lymph node-targeted immunization regimen co-targeting MART-1/Melan-A and tyrosinase In line with the finding that plasmid priming induces a population of antigen-specific T cells amenable to significant expansion upon cognate peptide boost, we show that pMEL-TYR plasmid priming followed by E-MEL and E-TYR peptide boost resulted in a significant expansion of MART-1/Melan-A 26-35-and tyrosinase 369-377-specific þ /Melan-A-specific T cells comparing pMEL-TYR plasmid-and E-MEL peptide-immunized mice. Statistical analysis was performed using one-way analysis of variance with a P-value of o0.01 comparing mRNA expression across duplicate pMEL-TYR plasmid, E-MEL peptide and naïve control gene arrays. Two-fold or higher changes in the level of mRNA expression were considered significant.
T cells as assessed by tetramer and IFN-g ELISPOT analysis and compared with plasmid priming alone (Figures 3a-d) . Furthermore, flow cytometric analysis showed a downregulation of CD62L expression in CD8 þ /tetramer þ T cells from HHD-1 mice primed with plasmid and boosted with peptide as compared with that in animals immunized with plasmid alone, consistent with an effector memory phenotype and allowing T-cell trafficking from lymphoid to non-lymphoid organs ( Figure 3e ).
As expected, and on the basis of previous observations, 27 ,30 intra-nodal vaccination was significantly more effective in inducing robust antigen-specific immune responses as compared with other routes of administration (Figure 4) . Furthermore, we now show that intranodal priming with pMEL-TYR plasmid and boosting with E-MEL and E-TYR peptides resulted in bivalent immunity, whereas plasmid alone, or peptide priming followed by plasmid boost, resulted in MART-1/Melan-A-specific T-cell responses but very low (or not detectable) tyrosinase-specific immunity (Figures 3 and 4) . Importantly, priming with a 'mock' plasmid by means of intra-nodal injection followed by peptide boost was not effective in eliciting a similar bivalent response, suggesting that plasmid-driven antigen expression was required for effective priming despite the intrinsic adjuvant effects of unmethylated CpG motifs (toll-like receptor 9) present in plasmid DNA (Figure 4) . This outlines the fact that the MART-1/Melan-A epitope is relatively dominant over the tyrosinase epitope within the context of the pMEL-TYR plasmid. However, peptide co-boost rescued the immune response against tyrosinase and elevated the immune response against the MART-1/Melan-A epitope (Figures 3b and d) .
To assess the functionality and specificity of T cells elicited by this immunotherapy regimen, lymph nodeimmunized mice were injected intravenously with labeled syngeneic splenocytes pulsed with MART-1/Melan-A 26-35 A27L and tyrosinase 369-377 peptides using a 'triplepeak' in vivo CFSE cytotoxicity assay. To build on previous findings that repeat plasmidprime and peptide-boost immunization cycles can maintain and, in some cases, further enhance T-cell immunity to specific antigens 22, 28 rather than inducing immune tolerance, we studied immune responses after a second immunization cycle. The percentage of MART-1/Melan-A 26-35 T cells in blood was significantly increased after a second cycle of intra-nodal immunization, whereas the tyrosinase 369-377-specific T-cell population was maintained. In addition, this experiment confirmed that peptide boost with either epitope resulted in significantly higher antigen-specific T-cell responses compared with plasmid immunization alone ( Figure 6 ).
Investigation of multi-targeted immunization through intra-lymph node, heterologous prime-boost vaccination
To generate T-cell immunity against multiple tumor antigens, HHD-1 mice were primed by intra-nodal injection with a mixture of two bivalent plasmids: (i) pMEL-TYR, expressing MART-1/Melan-A 26-35 and tyrosinase 369-377, and (ii) pNYE-SSX, expressing SSX2 41-49 and NY-ESO-1 157-165 (Table 2) . After plasmid priming, tetramer analysis showed immunity to MART-1/ Melan-A, SSX2 and NY-ESO-1 but the tyrosinase reactivity, consistent with the subdominant nature of this epitope, was not detected. Interestingly, T-cell immunity to the tyrosinase antigen could be rescued by a peptide boost with E-SSX and E-TYR, resulting in balanced immunity to all four antigens (Figure 7a Melan-A 26-35 epitope (Figure 7a ). Finally, a subset of immunized animals, selected on the basis of varying responses to individual epitopes, were challenged in vivo with human 624.38-NY melanoma target cells (co-expressing all four target antigens of interest) to compare the effectiveness of a balanced, multivalent immune response relative to prominent monovalent immunity biased against a single epitope. Animals that showed a balanced, multivalent immunity (Figures 7b  and c) were more effective at clearing these cells in vivo within a short time interval than monovalent responders or naı¨ve controls (Table 3) .
Discussion
In this study, we systematically evaluated the nature of the immune response resulting from DNA vaccination with the aim of optimizing this immunization approach for translation to the clinic. This was prompted by years of DNA vaccine research that has resulted in little translational success, as evidenced by the lack of a DNA vaccine or active immunotherapeutic agent approved for humans. In an earlier attempt to improve on DNA vaccination, we used a direct intra-lymph node injection approach to maximize the number of in situ transfected APCs and facilitate their interaction with T cells. Although the preclinical immunogenicity of this approach was superior to immunization using conventional means, 22 the immunological and clinical effects in humans were quite limited. 20, 21 More recently, we showed in a preclinical model that an epitope-specific peptide boost after DNA vaccination achieved a significant amplification of the immune response elicited by plasmid. 27 In addition, substantial immune responses achieved through intra-lymph node immunization with peptide and a TLR agonist were a prerequisite for effective control of tumor progression in immune-competent mice. 30 Therefore, we hypothesized that intra-lymph node DNA vaccination is an optimal priming strategy with the caveat that it is still not known whether a preferential induction of a specialized T-cell subset or simply a large expansion of TAA-specific T cells is crucial for the effectiveness of this category of vaccine. In addition, it has been reported that TLR agonists can activate TLR signaling and B7-H1 (PD-L1) expression on tumor cells resulting in T-cell suppression, 31, 32 although systemic exposure to TLR agonists is expected to be limited after intra-lymph node injection (data not shown).
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To characterize the potential of DNA or peptide as a priming agent, we performed a comparative global gene array analysis in mouse of specific T cells generated by intra-lymph node vaccination. Repeat administration of plasmid resulted in the induction of epitope-specific T cells with a strikingly different gene signature compared with peptide vaccination. A key distinction was uncovered at the level of gene transcripts corresponding to coinhibitory receptors, including PD-1, whose crucial regulatory role has been well documented. [33] [34] [35] [36] While T cells elicited by naked DNA vaccination had lower gene expression of PD-1 and other co-inhibitory receptors, T cells elicited by peptide alone had elevated levels of transcripts and protein for PD-1 ( Figure 2 and Table 1) , reminiscent of an 'exhausted' or 'pre-exhausted' phenotype described before in the context of chronic viral infection. 35 The low PD-1 expression profile resulting from DNA vaccination was consistent with that seen following co-immunization with moderate doses of peptide and a TLR9 agonist, 33 suggesting that low levels of antigen exposure in the presence of appropriate proinflammatory signals drive, at least in part, the resulting PD-1 low phenotype. Furthermore, a recently published study showed that intra-lymphatic DNA vaccination has an increased capability to induce CD62L þ central memory T cells, as opposed to more terminally differentiated (CD62L À ) memory and effector T cells, and showed that expression of PD-1 on antigen-specific CD8 þ T cells resulted in the suppression of proliferation. 27 Additional evidence also showed that blocking PD-1 on peptide-induced CD8 þ T cells restored their proliferative and functional capability, 33 strongly supporting the functional relevance of limited PD-1 expression triggered by DNA vaccination.
To our knowledge, this is the first report of an mRNA signature evaluation in T cells induced by DNA vaccination. These data highlight the potential of intra-lymphatic DNA vaccination to induce or replenish a population of PD-1 low T cells, refractory to immune exhaustion, and having the potential to be converted to potent effector T cells by boosting with conventional vectors. Beyond the evident implications in support of heterologous primeboost immunization strategies using DNA as a priming agent, these data support a rational approach toward characterizing and optimizing novel heterologous prime/ boost regimens based on priming agents that elicit T cells with reduced expression of co-inhibitory receptors.
Next, we investigated whether plasmid priming could also be used as an effective platform to elicit potent multivalent immune responses simultaneously against two or more tumor antigens. First, we showed that immunization with pMEL-TYR plasmid resulted in an unbalanced expansion of MART-1/Melan-A relative to tyrosinasespecific T cells. Boosting with peptide analogs administered into separate lymph nodes to avoid inter-epitope competition resulted in further expansion of MART-1/ Melan-A-specific T cells and triggered a robust population of tyrosinase-specific T cells. This shows that an Figure 7 Tetravalent immunity achieved by lymph node-targeted plasmid-prime, peptide-boost immunization. HHD-1 mice were immunized as described in Table 2 . (a) Animals primed with a mixture of the bivalent plasmids, pMEL-TYR and pNYE-SSX, and boosted with E-TYR and E-SSX peptides (Group-2) or E-TYR, E-SSX, E-NYE and E-MEL peptides (Group-3) generated tetravalent immunity as compared with the plasmid-only-immunized mice (Group-1). Proinflammatory cytokine production was measured on day 63 by IFN-g ELISPOT assay. The values represent the mean ± s.d. of the absolute number of SFC/spleen for each animal. Tetramer dot plots (b) and ELISPOTS (c) are shown for a selected animal from Group-2 (see Table 3 ) showing specific immunity to all four antigens as compared with results obtained from a naïve control. ELISPOT, enzyme-linked immunosorbent spot; IFN, interferon. optimized plasmid-priming/peptide-boost approach has the potential of co-inducing large populations of T cells specific for dominant and subdominant epitopes (Figure 3) . The level and quality of the T-cell response elicited using this preclinical HLA-A2 transgenic mouse model were sufficient to mediate in vivo clearance of syngeneic target cells and, importantly, yielded immunity capable of recognizing antigen-expressing human tumor cells ( Figure 5 ). In addition, repeat plasmid-prime and peptide-boost immunization resulted in the maintenance of immunity to both antigens with a significant increase of T-cell immunity against the dominant epitope and no evidence of immune tolerance against these antigens ( Figure 6 ). Finally, consistent with the model that while plasmid primes a balanced T-cell response encompassing central memory and peripheral memory/effector cells, and peptide drives the proliferation and differentiation of central memory T cells to peripheral memory/ effector cells, 22 repeat prime-boost immunization actually resulted in the maintenance and even slight elevation of T-cell immunity against the dominant epitope ( Figure 6 ). Together, these results show that plasmid-priming followed by peptide-boost using intra-lymph node delivery can achieve a robust priming and expansion (on the order of B1/10 CD8 þ T cells) of specific T cells against two distinct TAA epitopes, restricted to the same human leukocyte antigen (HLA) allele.
This approach could be extended to several antigens by co-priming with two bivalent plasmids, encoding MART-1/Melan-A 26-35, tyrosinase 369-377, NY-ESO-1 157-165 and SSX2 41-49 epitopes, and boosting with four peptide analogs corresponding to the same epitopes (Table 2 ). This regimen resulted in the induction of robust populations of T cells (in the range of B1/100-1/10 CD8 þ T cells) simultaneously against these four tumor epitopes restricted to the same HLA allele (Figure 7) . Whereas most immunized animals showed multivalent immunity, the few that did develop monovalent immunity mounted a substantial response against the most dominant epitope, MART-1/Melan-A 26-35. Interestingly, a balanced, tetravalent immunity was required for in vivo clearance of human tumor cells expressing these four antigens (Table 3 ). These data suggest that intra-lymph node priming with plasmid followed by boost with individual peptides could be a very effective means to elicit multivalent and robust immune responses against defined epitopes, restricted to the same HLA and borne by distinct TAA.
Finally, early-stage clinical testing is currently underway using similar investigational agents co-targeting two TAAs simultaneously (MKC1106-MT), to test the safety, feasibility and efficacy of this approach in patients with advanced melanoma. 
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